Used in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It works by inhibiting the complement C3 protein, a key component of the complement system involved in chronic inflammation and cell damage in the retina. By targeting C3, the antibody helps slow down the progression of retinal degeneration, preserving vision in patients with advanced dry AMD. Currently under clinical development as an intravitreal injection, it offers a targeted approach to modulate the immune response in the eye with high specificity and sustained effect.

Additionally, this anti-complement C3 reference antibody (NGM621) serves as a standard reference in research for developing or evaluating other antibodies with similar mechanisms, particularly in projects assessing complement system inhibition efficacy. Its use is significant both for targeted treatment of chronic diseases without cures and for supporting new drug development related to the immune system.